OR2T12

Across TCGA pan-cancer cohorts, OR2T12 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR2T12 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher OR2T12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR2T12 expression acts as an unfavorable survival marker.

GBM, LUSC, and LIHC are the cancer types where OR2T12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.024	0.416	<.001	12	view →
LUSC	OS	Median	III,IV	0.145	0.690	<.001	12	view →
LIHC	OS	Median	All	0.098	0.774	.001	7	view →
SARC	OS	Median	All	0.174	0.860	<.001	6	view →
PRAD	DFS	Median	All	0.131	0.888	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR2T12–GBM (OS)

Open the GBM breakdown →